DACPLAT
Categorie
DACPLAT Les marques, DACPLAT Analogs
DACPLAT Les marques melange
DACPLAT Formule chimique
DACPLAT RX lien
DACPLAT FDA fiche
DACPLAT msds (fiche de securite des materiaux)
DACPLAT Synthese de reference
DACPLAT Poids moleculaire
DACPLAT Point de fusion
DACPLAT H2O Solubilite
DACPLAT Etat
DACPLAT LogP
DACPLAT Formes pharmaceutiques
DACPLAT Indication
DACPLAT Pharmacologie
DACPLAT Absorption
DACPLAT Toxicite
DACPLAT Information pour les patients
Patients and patientsí caregivers should be informed of the expected side effects of ELOXATIN, particularly its neurologic effects, both the acute, reversible effects, and the persistent neurosensory toxicity. Patients should be informed that the acute neurosensory toxicity may be precipitated or exacerbated by exposure to cold or cold objects. Patients should be instructed to avoid cold drinks, use of ice, and should cover exposed skin prior to exposure to cold temperature or cold objects.
Patients must be adequately informed of the risk of low blood cell counts and instructed to contact their physician immediately should fever, particularly if associated with persistent diarrhea, or evidence of infection develop.
Patients should be instructed to contact their physician if persistent vomiting, diarrhea, signs of dehydration, cough or breathing difficulties occur, or signs of allergic reaction appear.
